In conclusion, MMP-HRP patients are younger compared to MMP-NO HRP patients, they also receive higher doses of methadone and had more intravenous use. The above findings imply that the early onset of high risk drug use and long-term exposure to heroin have more severe outcomes such as higher comorbidities (e.g. infectious diseases, medical and psychiatric disorders), and consequently, these patients are a more vulnerable group with a worse prognosis.
). Heroin dependence is a chronic problem with a history of relapse. It is a problem associated with medical and mental disorders, and is exacerbated if associated with intravenous heroin use Miguel-Arias, Pereiro, Bermejo, López de Abajo & Sobrino, 2016) .
Substitution programs with opioid agonists have demonstrated a high degree of efficacy and are currently the most widely used with patients with opioid dependence, as well as for reducing the prevalence of HIV infection (Amato, Davoli, Perucci, Ferri, Faggiano & Mattick, 2005; Fernandez-Miranda, García-Portilla, Sáiz, Gutiérrez & Bobes, 2001; MacArthur et al., 2014) . Observational studies demonstrate its usefulness in terms of treatment retention capacity in MMP, reduction of illicit drug use, high-risk practices, comorbidity and morbi-mortality (HIV, viral hepatitis) and associated crime, as well in as improvements regarding the employment and quality of life of addicts (Fernández-Miranda et al., 2001; Havinga, van der Velden, de Gee & van der Poel, 2014; Salamina et al., 2010) .
The response to methadone varies greatly (MarieClaire et al., 2016) , and some patients may require only low doses. However, methadone doses above 60-80 mg/ day and easy access to care and psychosocial services are linked to greater treatment adherence and decreased drug use, although psychiatric comorbidity and substance dependence overshadow the prognosis (Amato et al., 2005; Fernández-Miranda et al., 2001) .
It has been reported that among heroin addicts in opioid substitution treatment, 83% of patients present at least one clinical comorbidity, with 69% presenting some physical comorbidity and 59% and 40% with infectious and noninfectious comorbidity, respectively (Roncero et al., 2011) . There is also a high prevalence of mental illness in opioid users (Fernández-Miranda et al., 2001; Herrero, DomingoSalvany, Brugal, Torrens & Itinere Investigators, 2011; Roncero et al., 2016; San et al., 2016) with comorbidity in Axis I (52%) and Axis II (19%) (Roncero, et al., 2011) . The most common mental disorder is mood disorder and the spectrum of anxiety disorders, with a lifetime prevalence of between 4% and 54%; The prevalence of other major psychiatric disorders such as schizophrenia, obsessive-compulsive disorder and eating disorders is lower (Astals, Díaz, Domingo-Salvany, Martín-Santos, Bulbena & Torrens, 2009) .
Programs associated with treatment intervention in chronic drug users, in which heroin addicts have a significant percentage, are harm reduction programs (HRPs) (International Harm Reduction Association [IHRA], 2009) . HR refers to policies, programs and practices that seek to reduce the health, social and economic consequences associated with the use of psychoactive drugs among people who cannot or do not want to stop consumption (Daigre et al., 2010; IHRA, 2009) . The main focus is on the prevention of harm for people who continue to use drugs, so these programs are included within tertiary prevention (Rhodes & Hedrich, 2010; Torrens, Fonseca, Castillo & Domingo-Salvany, 2013) . Its objectives are to minimize the medical and psychopathological complications caused by drug use, to promote less invasive or dangerous methods of use, to teach healthy hygienedietary habits, to bring the patient progressively closer to healthcare resources and finally to encourage abstinence (IHRA, 2009) . A particularly vulnerable group is young people, where a steady increase in rates of illicit drug use and related deaths from overdose, especially among those injecting the drugs, has been noted. Studies have shown that being young, frequently arrested, and with moderate/ heavy alcohol use alongside recent hospitalization for methadone detoxification increases the risk of overdose (Seal, Kral, Gee, Moore, Bluthenthal, Lorvick, & Edlin, 2001) .
HRPs provide partial and/or palliative measures for heavy users or those at risk of social exclusion. They seek to prevent the most prevalent infections (syringe exchange programs and distribution of condoms) and increase the control and treatment of organic and psychiatric disease associated with drug use (easy access close to health services). In Spain, methadone treatment programs at the public level began in 1985, although they did not expand until the 1990s with therapeutic and HR approaches. Syringe exchange programs (SEPs) were also started around the same time, with facilities for selfinjection use or supervised consumption included in 2000 (Martínez-Luna, Palma-Álvarez & Roncero, 2016) .
The aims of the study are to compare patients in MMPs who use MMP-HRP services to patients in MMP-NO HRP. It is hypothesized that MMT-HR patients have greater addiction severity and greater comorbidity in both physical (HIV, Hepatitis C) and mental diseases, with more clinicalpsychopathological complexity than MMP-NO HRP.
Method
The study was carried out at the Vall d'Hebron Outpatient Drug Clinic (CAS). The data were collected from January 2006 to January 2016. Inclusion criteria were: to be over 18 years, present opioid dependence according to DSM IV-TR and DSM-5 criteria, sign informed consent and to complete the assessment process, the protocol of which had previously been approved by the Hospital Ethics Committee. Exclusion criteria were: to show signs of intoxication, severe somatic illness, severe cognitive impairment and language barrier, all of which were checked in the baseline interview. Patients received no financial compensation for their participation in the study. This paper is part of wider research on comorbidity in patients with substance dependence disorders.
Of the 225 patients who met the diagnostic criteria for opioid dependence disorder or moderate/severe drug use disorder according to DSM-IV-TR criteria (2006 and DSM-5 (2014 DSM-5 ( -2016 and were in MMP, 143 patients completed the psychological assessment protocol. The sample was divided into two groups: the first consisted of patients in PMM-NO HRP (n=101) and the second was composed of patients in MMP-HRP (n=42). To be included in the latter group patients needed to have used 2 or more harm reduction services (syringe exchange, supervised drug consumption room, overdose workshop).
We also performed a subanalysis of those under the age of 45 in the final group of 143 patients. This subanalysis was based on an approximate calculation of the generation of users to whom HRP services began to be offered in a generalized manner in Spain. The sample was divided between the generation previous to HRP (older than 45) and the generation after the start of HRP (under 45), which left a sample of 116 patients, with 78 patients in the MMP-NO HRP group and 38 in the MMP-HRP group.
Variables and Instruments
Three diagnostic interviews were performed by trained psychologists to collect sociodemographic data (sex, age, nationality, level of education), variables related to opioid use (age of dependence onset, quantity consumed, methadone dosage). The instruments used were:
-A sociodemographic and clinical questionnaire developed ad hoc by our unit that includes infectious diseases (HIV, tuberculosis, etc.) and hepatic diseases (hepatopathies, cirrhosis, infectious hepatitis or other hepatitis) (Grau-López et al., 2012 ). -The Spanish version (Bobes, González, Saiz & Bousoño, 1996) of EuropASI, the European adaptation of the Addiction Severity Index (Kokkevi & Hartgers, 1995) . This structured and heterogeneous clinical interview explores the following areas: medical problems, employment status/support, alcohol/drug use, legal problems, social and family relationships and psychological state. Composite scores have been used to control the interviewer's degree of subjectivity. -SCID-I (Semi-structured Clinical Interview for DSM-IV Axis I Disorders) ). -SCID-II (First, Gibbon, Spitzer, Williams & Smith, 1999) . The instruments were used regardless of whether the clinical diagnosis was performed using DSM-IV-TR and/or DSM-V criteria.
Data analysis
Descriptive, bivariate and multivariate analyses were performed, and all variables are described in terms of percentages, means and standard deviations. For the 
Results

Clinical, sociodemographic and drug use variables of the total sample
The bivariate analysis yielded differences in age (39.53 ± 8.20 vs 34.83 ± 7.37, p ≤ .01), with MMP-HRP patients found to be younger. No significant differences were observed, however, with regard to clinical variables such as medical history (infectious and hepatic diseases) and psychiatric history (affective, personality, psychotic and anxiety disorders).
In terms of the drug use variables, 56.3% of the patients in the sample take it intravenously. As for smoking the drug, this method is used more frequently by MMP-NO HRP patients than by MMP-HRP patients (22.3% vs 4.9%, p ≤ .01). Regarding methadone dosage, 62.7% of MMP-NO HRP patients have doses below 40 mg compared to 41.7% of the MMP-HRP group (p ≤ .046), although the difference is not statistically significant after the Bonferroni correction.
Clinical, sociodemographic and drug use variables of patients under 45
A subanalysis by age of the under 45 group shows that MMP-HRP patients are younger (36.54 ± 6.10 vs 33.42 ± 6.19, p ≤ .05) and 58.1% of the patients MMP-HRP have liver diseases. With regard to such diseases in the total sample, a subanalysis was performed in patients over 45 years of age which yielded a significant difference in the presence of liver diseases in MMP-HRP patients (.035). Comparing the MMP-HRP patients revealed that the MMP-HRP group of under 45s had a lower prevalence of liver diseases.
Regarding drug use variables, MMP-HRP patients used the intravenous route more (5.9% vs 70.3%, p ≤ .05), whereas the MMP-NO HRP group made greater use of the smoked route (24.3% vs 5.4 %, p ≤ .05).
Psychiatric comorbidity
There are no differences in psychiatric comorbidity in Axis I in any of the analyses performed in this study. There is a statistically significant difference in Cluster B personality disorders, but this difference is not statistically significant after the Bonferroni correction is performed.
Finally, the results obtained in the EuropASI interview showed that in the total sample, significant differences are only found in relation to drugs (.219 ± .148 vs .333 ± .204, p ≤ .01), with greater severity in the MMP-HRP group.
In an analysis of the results obtained for the sample of under 45s, significant differences were found not only on 
Multivariate analysis
A logistic regression analysis was performed to detect the variables related to severity in the MMP-HRP group so that all the variables of the earlier bivariate analysis that were statistically significant after the Bonferroni correction could be analyzed. For the total sample, these variables were: age, smoked route and severity of addiction on the drugs subscale. These three variables remained significant factors in the model.
For the under 45 sample, the variables involved were: age, intravenous route, smoked route and severity of addiction in drug and family subscales. Only age, smoked route and severity of addiction on the drug subscale remained significant factors in the model. Intravenous route and severity of addiction were excluded from the family subscale. 
Discussion
There are differences between MMP patients who use harm reduction (MMP-HRP) and MMP patients who do not (MMP-NO HRP), with MMP-HRP patients being younger. There are currently no studies that specifically link this data, although some studies point to the importance of age, since younger people have less adherence to HRP programs and greater difficulty in accessing services of the same type (Krug, Hildebrand & Sun, 2015) . Earlier onset and longer exposure to high-risk drug use practices among the MMP-HRP group would result in a higher risk of medical and psychiatric comorbidity (Hopfer, Khuri, Crowley & Hooks, 2002) . MMP-HRP patients have a higher frequency of liver diseases (55.6% vs 38%, .053); moreover, patients over 45 years of age in this group present a significant difference (.035), which has already been described in the literature on patients using syringe exchange programs or drug consumption facilities, who have a high prevalence of mental illness, HIV, and hepatitis C (Havinga et al., 2014; Herrero, Domingo Salvany, Brugal, Torrens & Itinere Investigators, 2011; Wang, Zhang & Ho, 2011) .
Although the existence of Cluster B disorders in MMP patients is expected (Paversen, Masoudi, Majidi-Tabrizi & Mazhari, 2012; Roncero et al., 2016) , more than half of the MMP-HRP group has one of these disorders, which can be seen as a marker of severity since personality disorders in MMP have been associated with a worse prognosis (Peles, Schreiber, Domany & Adelson, 2014) . However, given that the differences are not significant we should be cautious when interpreting personality disorders.
Mental disorders in MMP patients have been associated with worse quality of life (Teoh Bing Fei, Yee & Habil, 2016) , and although there are no differences between the two groups, it should be noted that in the total sample other mental disorders are highly prevalent, confirming previous findings among heroin addicts in MMP (Paversen et al., 2012 , Pereiro et al., 2013 Roncero et al., 2016) . This would indicate that the consumption of opioids is serious in itself, independently of the use of HRP resources.
Clinically, it must be stressed that more than half of the sample studied had induced psychotic disorders, with no differences between the MMP-HRP and MMP-NO HRP groups. It is not surprising that these patients suffer psychoses, since approximately 60% are also cocaine dependent, a state which has been widely associated with the presence of psychotic symptoms (Roncero et al., 2017) , especially in the group of cocaine self-injectors that receive low doses of methadone (Roncero et al., 2013b) . Moreover, the presence of psychotic symptoms in addicts is a variable that affects other mental disorders with greater severity and comorbidity (Roncero et al., 2017; Roncero et al., 2013a) . In terms of the route of administration, it is already known that patients who use HRP resources tend to favor intravenous use independently of the drug involved (MacArthur et al., 2014) , which is why the exchange of syringes and supervised injection facilities were the initial founding programs HRP (IHRA, 2010) . Our findings corroborate this by identifying greater intravenous use (5.9% vs. 70.3%, .017) in the MMP-HRP group, while in the MMP-NO HRP group, the smoked route was preferred (24.3% vs. 5.4 %, .011). The route of administration is important because of the risks involved with intravenous use, given the greater exposure to infectious diseases (hepatitis B and C and HIV) and the medical complications that derive from these diseases (Palmateer, Kimber, Hickman, Hutchinson, Rhodes & Goldberg, 2010) . Strategies are therefore needed to reduce the risk of infection and associated morbidity and mortality (MacArthur et al., 2014) .
Regarding methadone dosage, it should be noted that the MMP-HRP group take higher doses of methadone compared to the MMP-NO HRP, where lower doses (less than 40 mg/day) are the norm. Yet in both groups the dosage interval is small in relation to that suggested in the literature (Faggiano, Vigna-Taglianti, Versino, & Lemma, 2003) . Low doses of methadone in the MMP-HRP group are associated with what the literature describes in a population with a harm reduction profile, where abstinence is not the main objective and the dose is part of a program with a low level of expectation typical of low-threshold MMPs (Kwan, Wong & Lee, 2015) . It can be hypothesized that low doses of methadone in the MMP-NO HRP group are related to patient resistance to continue taking doses above 60 mg and the fear of complete methadone withdrawal.
The assessment of drug use severity in the MMP-HRP group through the EuropASI interview showed differences in the total sample in the drug subscale, with greater severity in the MMP-HRP group. Previous studies have already pointed to the fact that HRP patients are generally at a more severe stage of addiction (McNeil, Kerr, Pauly, Wood & Small, 2016) . Furthermore, in the under 45 sample, differences were found in both the drug and family subscales, which would imply that MMP-HRP patients have less social support (Jhanjee, Lal, Mondal & Jain, 2011) . This fact highlights the importance of HRP services for young patients, with greater addiction severity and less social support.
As was found in the regression analysis, MMP-NO HRP patients use other routes of administration (smoked) more frequently, implying lower risk, and the lack of family support no longer appears so relevant. The differences in variables such as age, the route of administration and greater severity of use according to EuropASI (drug subscale) revealed by the MMP-HRP group confirm the results of previous studies indicating that patients who use HRP services are a group with greater vulnerability both at the health and social level (Havinga et al., 2014; IHRA, 2009 ). Although we expected the study to yield more differences between the two groups at medical and psychiatric levels, the differences found are important because the variables involved are relevant and highlight the greater severity among the MMP-HRP group, a fact that to our knowledge has not previously been described in Spain.
The limitations of the study are related to sample size, which can be explained by the complexity involved in performing a complete assessment with HRP patients. A further limitation is the methadone dosage patients receive, since it is not specified at which stage of the MMP the patients were (induction, maintenance, withdrawal). In addition, our data are not very comparable because of the lack of previous research analyzing differences between patients using MMP-HRP and MMP-NO HRP. Finally, it should be remembered that HRP programs are tools for the treatment and psychosocial support of patients with high severity and are also valued positively by the users themselves (Daigre et al., 2010) since they complement the care offered to patients who do not seek or cannot achieve total abstinence.
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